Healthcare / Diagnostics & ResearchWarsaw
$173.10
+12.40 (+7.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $282.7M · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.8B
P/E
23.2x
↑EV/EBITDA
11.8x
↓ROE
47.6%
↑Gross Margin
79.0%
↑Debt/Equity
2.05
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.9%
FCF CAGR
+21.3%
FCF margin
14.4%
FCF / Net income
1.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.41B · net income $251.6M · FCF $347.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.41B | $2.41B | $1.95B | $1.59B | $1.44B |
| Net Income | $251.6M | $251.6M | $223.3M | $123.4M | $167.4M |
| EBITDA | $587.5M | $587.5M | $510.1M | $375.1M | $380.5M |
| EPS | — | — | 6.62 | 3.66 | 4.96 |
| Gross Margin | 79.0% | 79.0% | 78.5% | 65.1% | 65.2% |
| Operating Margin | 15.9% | 15.9% | 17.3% | 14.7% | 17.6% |
| Net Margin | 10.4% | 10.4% | 11.5% | 7.8% | 11.7% |
| Balance Sheet | |||||
| Debt/Equity | 2.05 | 2.05 | 2.32 | 2.62 | 2.31 |
| Current Ratio | 0.73 | 0.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $347.0M | $347.0M | $282.7M | $254.7M | $194.5M |
| Returns | |||||
| ROE | 47.6% | 47.6% | 53.3% | 38.0% | 53.6% |
| Valuation | |||||
| P/E | 23.23 | 23.23 | — | — | — |
| EV/EBITDA | 11.75 | 11.75 | — | — | — |
| P/B | 11.06 | 11.06 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 23.6% | 23.6% | 22.8% | 10.6% | — |
| EPS Growth | — | — | 80.9% | -26.3% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.1%
Start / end P/E
n/dx → n/dx
EPS bridge
6.62 → n/d
Residual
+4.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.